RxDoctor Payments Data

Brett Volpe, MD

Pulmonary Disease · Meriden, CTNPI 1235116948

Payments from drug & device makers

$2,451in general payments, 2019–2025

Across 66 payments — averaging $37.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$464
  • Jazz Pharmaceuticals Inc.$393
  • Mallinckrodt Hospital Products Inc.$309
  • Actelion Pharmaceuticals US, Inc.$239
  • AstraZeneca$204
  • Eisai Inc.$148
  • plus $693 from 8 others

What the payments were for

  • Food & beverage$2,451100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,451 in reported general payments places this provider in the 55th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$117,180
Medicare patients
309
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate15$300,132
WakixPitolisant Hcl12$190,720
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$59,040
SunosiSolriamfetol Hcl32$35,977
Breo ElliptaFluticasone/Vilanterol49$26,072
NeuproRotigotine13$10,779
Armodafinil73$6,851
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,857
Wixela InhubFluticasone Propion/Salmeterol14$2,377
Modafinil38$2,077
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,053
Doxepin Hcl52$1,931
Albuterol Sulfate HfaAlbuterol Sulfate70$1,291
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$978
Pramipexole DihydrochloridePramipexole Di-Hcl92$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$146$190,72012 claims
GSKTrelegy Ellipta, Breo Ellipta$464$85,111114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →